Loading organizations...
§ Venture Capital · 22 Station Road, Cambridge, United Kingdom, CB1 2JD
Venture capital firm investing in early-stage life sciences and deep tech companies from the Cambridge ecosystem.
Cambridge Innovation Capital is a venture capital firm based in Cambridge, United Kingdom, that invests in early-stage life sciences and deep tech companies emerging from the local University of Cambridge ecosystem. The firm primarily targets seed through Series A funding rounds and has raised approximately £650 million across its investment vehicles to bridge the gap between academic research and commercialization. To date, the organization has supported around 40 portfolio companies and committed £100 million to back university spinouts through an Entrepreneur-in-Residence program. Under the leadership of Managing Partner Andrew Williamson, the firm also established two accelerators, Deeptech Labs and Start Codon, with the latter backing 28 healthcare startups. The firm's broader investment portfolio includes therapeutics and medical technology businesses such as Immutrin and TRIMTECH Therapeutics, providing capital and strategic guidance. Cambridge Innovation Capital was founded in 2014.
Key people at Cambridge Innovation Capital.
Key people at Cambridge Innovation Capital.
Cambridge Innovation Capital (CIC) is a leading venture capital firm specializing in early-stage investments in cutting-edge life sciences and deep technology companies, with a strong focus on AI, IoT, quantum technologies, and healthcare innovations. Its mission is to back world-leading ventures emerging from the Cambridge ecosystem, providing long-term capital and strategic support to help startups scale and achieve market leadership. CIC’s investment philosophy centers on deep sector expertise, leveraging its unique partnership with the University of Cambridge and its extensive network to identify disruptive technologies with high commercial and societal impact. The firm actively supports companies from seed through scale-up stages, fostering innovation that drives advances in therapeutics, medtech, diagnostics, digital health, genomics, and deep tech sectors[1][2][3][4].
Founded in 2014, CIC was established through a unique relationship with the University of Cambridge, positioning it as a preferred investor with unparalleled access to the university’s research and innovation pipeline. Key partners include experienced venture professionals and entrepreneurs, supported by a distinguished panel of technical and commercial advisors. Over time, CIC has evolved from primarily seed and Series A investments to also providing growth capital and operational support, helping around 40 companies raise over £600 million. The firm also operates an Entrepreneur-in-Residence (EIR) program that connects experienced founders and technologists with Cambridge’s academic community to commercialize early-stage innovations[2][4].
CIC rides the wave of increasing convergence between advanced science and technology, particularly in AI, quantum computing, IoT, and healthcare innovation. The timing is critical as these sectors are undergoing rapid transformation driven by breakthroughs in computational power, data analytics, and biotechnologies. Market forces such as growing demand for precision medicine, sustainable technologies, and autonomous systems align with CIC’s investment focus. By nurturing startups at the intersection of academia and industry, CIC plays a pivotal role in accelerating commercialization of disruptive technologies, influencing both the Cambridge ecosystem and the broader European innovation landscape[1][2][3].
Looking ahead, CIC is poised to deepen its impact by continuing to scale its portfolio companies and expanding its support infrastructure, including further integration of ESG and societal impact considerations into its investment strategy. Trends such as AI-driven healthcare, quantum-enabled computing, and IoT-enabled smart systems will likely shape its future investments. CIC’s unique positioning within one of the world’s foremost innovation hubs ensures it will remain a key catalyst for translating scientific breakthroughs into global market successes, reinforcing its role as a bridge between pioneering research and commercial impact[2][4].
Cambridge Innovation Capital has more than 26 tracked investments across 23 companies. The latest tracked deal is $10.0M Seed Extension in BeyondMath in February 2026.
